Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708903 · ClinicalTrials.gov registry record · Phase 1
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
A Phase 1 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00708903 is a Phase 1 study that has completed, run by Puma Biotechnology. The registered enrollment target is 60 participants.
The verdict
NCT00708903, a Phase 1 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether HKI-272 affects the rhythms of the heart (cardiac repolarization).
Interventions
- OTHER Placebo
- DRUG Moxifloxacin
- DRUG neratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00708903
The ClinicalTrials.gov registry entry for NCT00708903 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00708903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00708903 about?
NCT00708903 is a clinical study titled "Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)". The purpose of this study is to determine whether HKI-272 affects the rhythms of the heart (cardiac repolarization).
What is the current status of trial NCT00708903?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00708903?
The interventions under investigation include: Placebo (OTHER), Moxifloxacin (DRUG), neratinib (DRUG).
Who is sponsoring clinical trial NCT00708903?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.